Literature DB >> 24933532

Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases.

Ruud P W Litjens1, Tibor M Brunt2, Gerard-Jan Alderliefste3, Remco H S Westerink4.   

Abstract

Hallucinogen persisting perception disorder (HPPD) is a drug-induced condition associated with inaccurate visual representations. Since the underlying mechanism(s) are largely unknown, this review aims to uncover aspects underlying its etiology. Available evidence on HPPD and drug-related altered visual processing was reviewed and the majority of HPPD cases were attributed to drugs with agonistic effects on serotonergic 5-HT₂A receptors. Moreover, we present 31 new HPPD cases that link HPPD to the use of ecstasy (MDMA), which is known to reverse serotonin reuptake and acts as agonist on 5-HT₂A receptors. The available evidence suggests that HPPD symptoms may be a result from a misbalance of inhibitory-excitatory activity in low-level visual processing and GABA-releasing inhibitory interneurons may be involved. However, high co-morbidities with anxiety, attention problems and derealization symptoms add complexity to the etiology of HPPD. Also, other perceptual disorders that show similarity to HPPD cannot be ruled out in presentations to clinical treatment. Taken together, evidence is still sparse, though low-level visual processing may play an important role. A novel finding of this review study, evidenced by our new cases, is that ecstasy (MDMA) use may also induce symptoms of HPPD.
Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  5-HT(2A) receptor; Ecstasy; HPPD; Hallucinogen; LSD; MDMA

Mesh:

Substances:

Year:  2014        PMID: 24933532     DOI: 10.1016/j.euroneuro.2014.05.008

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  10 in total

1.  Acquired synaesthesia following 2C-B use.

Authors:  Steliana Yanakieva; David P Luke; Ashok Jansari; Devin B Terhune
Journal:  Psychopharmacology (Berl)       Date:  2019-04-26       Impact factor: 4.530

Review 2.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

Review 3.  Novel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs.

Authors:  Zurina Hassan; Oliver G Bosch; Darshan Singh; Suresh Narayanan; B Vicknasingam Kasinather; Erich Seifritz; Johannes Kornhuber; Boris B Quednow; Christian P Müller
Journal:  Front Psychiatry       Date:  2017-08-18       Impact factor: 4.157

Review 4.  Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives.

Authors:  Giovanni Martinotti; Rita Santacroce; Mauro Pettorruso; Chiara Montemitro; Maria Chiara Spano; Marco Lorusso; Massimo di Giannantonio; Arturo G Lerner
Journal:  Brain Sci       Date:  2018-03-16

Review 5.  Symptoms related to the visual system in migraine.

Authors:  Robin M van Dongen; Joost Haan
Journal:  F1000Res       Date:  2019-07-30

Review 6.  Substance-Induced Psychoses: An Updated Literature Review.

Authors:  Alessio Fiorentini; Filippo Cantù; Camilla Crisanti; Guido Cereda; Lucio Oldani; Paolo Brambilla
Journal:  Front Psychiatry       Date:  2021-12-23       Impact factor: 4.157

7.  The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.

Authors:  James J Rucker; Lindsey Marwood; Riikka-Liisa J Ajantaival; Catherine Bird; Hans Eriksson; John Harrison; Molly Lennard-Jones; Sunil Mistry; Francesco Saldarini; Susan Stansfield; Sara J Tai; Sam Williams; Neil Weston; Ekaterina Malievskaia; Allan H Young
Journal:  J Psychopharmacol       Date:  2022-01-04       Impact factor: 4.153

8.  Pathological Delta Oscillations in Hallucinogen Persisting Perception Disorder: A Case Report.

Authors:  David Haslacher; Nikolina Novkovic; Maria Buthut; Andreas Heinz; Surjo R Soekadar
Journal:  Front Psychiatry       Date:  2022-03-24       Impact factor: 4.157

Review 9.  Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.

Authors:  Joost J Breeksema; Bouwe W Kuin; Jeanine Kamphuis; Wim van den Brink; Eric Vermetten; Robert A Schoevers
Journal:  J Psychopharmacol       Date:  2022-08-26       Impact factor: 4.562

Review 10.  Alice in Wonderland syndrome: A systematic review.

Authors:  Jan Dirk Blom
Journal:  Neurol Clin Pract       Date:  2016-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.